numer
kampo
medicin
orient
herb
use
treatment
infecti
diseas
sever
reason
genet
background
econom
reason
fewer
advers
effect
chapter
describ
kampo
medicin
relat
orient
herb
effect
promis
treatment
infecti
diseas
clinic
level
andor
anim
model
addit
effect
kampo
medicin
test
vitro
culturedcel
studi
also
includ
chapter
section
categor
infecti
diseas
accord
popular
kampo
medicin
influenza
viru
infect
caus
annual
epidem
recur
pandem
seriou
impact
public
health
global
economi
antiinfluenza
agent
oseltamivir
zanamivir
effect
neuraminidaseresist
virus
due
cumul
mutat
neuraminidas
found
moscona
weinstock
zuccotti
drug
expens
lowincom
countri
sever
kampo
medicin
propos
effect
complementari
altern
medicin
viral
infect
stimul
host
immun
system
directli
act
viru
growth
shoseiryuto
use
symptom
runni
nose
cough
allerg
rhiniti
bronchiti
ikeda
et
al
report
shoseiryuto
possess
antiinfluenza
activ
vivo
first
describ
replic
viru
nasal
caviti
spread
viru
lung
effici
inhibit
intranas
infect
mouseadapt
influenza
strain
balbc
mice
shoseiryuto
oral
administ
nagai
yamada
shoseiryuto
increas
antivir
iga
antibodi
nasal
bronchoalveolar
wash
infect
mice
stimul
type
interferon
ifn
induct
studi
nagai
yamada
howev
vitro
studi
human
cell
line
suggest
shoseiryuto
show
type
ifnmedi
inhibit
virus
ganciclovirresist
human
cytomegaloviru
murayama
et
al
human
respiratori
syncyti
viru
chang
et
al
regard
influenza
viru
infect
report
inhibitori
effect
viral
growth
shoseiryuto
culturedcel
system
antiinfluenza
activ
shoseiryuto
like
immunostimul
adjuvantlik
activ
direct
action
viru
case
therefor
propos
shoseiryuto
use
treatment
influenza
viru
infect
histori
influenza
viru
infect
andor
influenza
vaccin
adjuv
yamada
nagai
fact
group
explor
activ
ingredi
shoseiryuto
test
influenza
adjuv
activ
oral
administr
one
ingredi
pinel
acid
mice
influenza
hemagglutinin
ha
vaccin
enhanc
antivir
iga
antibodi
nasal
bronchoalveolar
wash
suggest
pinel
acid
may
provid
safe
potent
oral
adjuv
nasal
influenza
ha
vaccin
nagai
et
al
involv
adjuv
activ
anoth
kampo
medicin
also
investig
human
subject
highrisk
group
influenza
infect
juzentaihoto
kampo
medicin
tradit
use
patient
anemia
anorexia
fatigu
also
abil
acceler
recoveri
hematopoiet
injuri
induc
radiat
anticanc
drug
mitomycin
c
hisha
et
al
influenza
adjuv
activ
juzentaihoto
test
use
subject
minimum
age
year
measur
antibodi
titer
influenza
vaccin
saiki
et
al
investig
indic
signific
increas
hemagglutin
inhibit
titer
among
test
vaccin
strain
b
howev
mechan
underli
specif
juzentaihoto
strain
remain
discov
although
studi
report
juzentaihoto
stimul
respons
affect
respons
transcript
factor
munakata
et
al
antiinfluenza
kampo
medicin
affect
cytokin
antimicrobi
peptid
product
report
hochuekkito
kampo
medicin
use
treat
function
condit
gener
fatigu
compromis
state
gastrointestin
motil
disord
yanagihara
et
al
hochuekkito
administ
oral
day
influenza
viru
infect
found
increas
surviv
rate
suppress
viral
growth
bronchoalveolar
lavag
fluid
inhibit
lung
index
mice
administr
hochuekkito
mice
elev
concentr
bronchoalveolar
lavag
fluid
decreas
inflammatori
cytokin
interleukin
il
granulocytemacrophag
coloni
stimul
factor
tumor
necrosi
factor
mori
et
al
furthermor
report
hochuekkito
enhanc
express
antimicrobi
peptid
defensin
mice
compar
control
subject
dan
et
al
synergist
antiinfluenza
effect
hochuekkito
oseltamivir
phosphat
also
report
mice
ohgitani
et
al
furthermor
clinic
studi
indic
preoper
administr
hochuekkito
may
amelior
excess
postop
inflammatori
respons
prolong
immunosuppress
state
result
fewer
postop
infecti
complic
iwagaki
saito
anoth
antiinfluenza
kampo
medicin
shahakusan
report
affect
cytokin
mrna
express
level
mandibular
lymph
node
lung
influenzainfect
mous
model
kampo
medicin
prescrib
late
phase
infect
caus
inflamm
lung
shahakusan
administ
oral
day
day
infect
influenza
strain
upper
respiratori
tract
significantli
decreas
viru
titer
nasal
lavag
fluid
lower
mrna
contrast
mrna
increas
infect
mice
condit
addit
shahakusan
decreas
infiltr
inflammatori
cell
bronchiol
stimul
natur
killer
nk
cell
activ
howev
shahakusan
direct
effect
influenza
growth
life
cycl
hokari
et
al
sever
studi
kampo
medicin
directli
act
influenza
life
cycl
report
herbal
extract
ephedra
inhibitori
effect
growth
influenza
viru
mantani
et
al
entri
influenza
viru
host
cell
acidif
lysosom
endosom
wellknown
factor
yoshimura
et
al
extract
ephedra
herba
inhibit
acidif
endosom
lysosom
madindarbi
canin
kidney
mdck
cell
lead
growth
inhibit
influenza
viru
treat
immedi
min
infect
chemic
inhibit
experi
suggest
tannin
one
activ
compon
inhibit
extract
maoto
contain
ephedra
use
earli
phase
influenza
infect
efficaci
influenza
viru
infect
demonstr
oral
administr
maoto
h
postinfect
significantli
reduc
viru
titer
nasal
bronchoalveolar
lavag
fluid
aj
mice
nagai
et
al
treatment
increas
antiinfluenza
viru
igm
iga
antibodi
titer
nasal
fluid
bronchoalveolar
lavag
fluid
serum
respect
show
effect
similar
shoseiryuto
clinic
random
studi
also
claim
maoto
may
effect
case
influenza
low
sensit
oseltamivir
younger
patient
year
age
kubo
nishimura
toriumi
et
al
transcinnamaldehyd
ca
one
princip
compon
essenti
oil
deriv
cinnamomi
cortex
antiinfluenza
activ
vitro
vivo
hayashi
et
al
micromolar
level
ca
significantli
inhibit
viral
growth
mdck
cell
infect
influenza
viru
inhal
mous
cage
mgcage
per
day
intranas
administr
ca
per
day
significantli
increas
surviv
rate
influenza
virusinfect
mice
viru
yield
bronchoalveolar
lavag
fluid
time
lower
inhal
treatment
ca
compar
control
treatment
find
suggest
cinnamomi
cortexcontain
kampo
medicin
effect
acut
respiratori
infecti
diseas
hepat
c
viru
hcv
infect
signific
worldwid
problem
public
health
standard
care
hcv
combin
therapi
pegyl
ribavirin
ribavirinifn
treatment
effect
enough
hcv
genotyp
show
seriou
side
effect
influenzalik
symptom
mental
health
problem
hematolog
abnorm
although
ifnfre
ledipasvirsofosbuvir
medic
enorm
impact
effect
treatment
chronic
hcv
genotyp
smith
et
al
therapi
could
still
expens
lowincom
countri
high
preval
hcv
sever
kampo
medicin
andor
natur
product
report
antihcvag
complementari
altern
medicin
ninjinyoeito
kampo
medicin
use
treatment
athrepsia
due
surgeri
anorexia
cold
constitut
anemia
activ
compon
gomisin
schisandra
fruit
among
herb
includ
ninjinyoeito
report
inhibitori
effect
hcv
protect
effect
immunolog
hepatopathi
hcv
infect
cyong
et
al
ninjinyoeito
report
antiinflammatori
properti
suppress
phagocytosi
alveolar
macrophag
aoki
et
al
increas
nk
activ
healthi
individu
kamei
et
al
also
antioxid
hepatoprotect
activ
cell
cultur
system
kamei
et
al
vivo
model
egashira
et
al
base
find
cyong
et
al
identifi
activ
antihcv
compon
ninjinyoeito
gomisin
culturedcel
system
anim
model
immunolog
induc
acut
hepat
failur
studi
also
demonstr
clinic
effect
use
ninjinyoeito
treat
chronic
hcv
howev
result
conclus
studi
need
assess
promis
ninjinyoeito
treatment
chronic
hcv
azzam
et
al
may
reduc
viral
load
contribut
delay
hcv
progress
shosaikoto
use
patient
liver
diseas
japan
suppress
effect
cancer
develop
liver
macrobiot
effect
assess
mechanist
aspect
vitro
studi
test
effect
shosaikoto
product
circul
mononuclear
cell
liver
cirrhosi
patient
yamashiki
et
al
group
determin
level
monocytemacrophag
fraction
lymphocyt
fraction
peripher
blood
obtain
hcvposit
liver
cirrhosi
patient
healthi
subject
found
produc
patient
significantli
lower
produc
healthi
subject
shosaikoto
stimul
monocytemacrophag
fraction
lymphocyt
fraction
increas
level
threefold
almost
level
healthi
subject
studi
conclud
one
possibl
mechan
macrobiot
effect
shosaikoto
liver
cirrhosi
patient
may
improv
product
phase
ii
trial
shosaikoto
conduct
hcv
patient
candid
ifnbas
therapi
determin
effect
studi
deng
et
al
trial
chronic
hcv
patient
oral
administ
g
shosaikoto
three
time
daili
month
improv
aspart
aminotransferas
alanin
aminotransferas
observ
patient
studi
respect
viral
load
reduc
patient
increas
patient
affect
patient
studi
conclud
shosaikoto
may
improv
liver
patholog
select
hcv
patient
candid
ifnbas
treatment
larger
control
studi
necessari
oxymatrin
one
major
alkaloid
compon
sophora
flavescen
first
describ
antihcv
antihepat
b
viru
hbv
effect
cell
cultur
model
chen
et
al
anim
model
chen
et
al
mous
studi
indic
oxymatrin
hepatoprotect
activ
acut
liver
injuri
induc
allyl
alcohol
liu
et
al
antifibrot
activ
oxymatrin
dgalactosamineinduc
rat
liver
fibrosi
predict
partli
inhibit
lipid
peroxid
immunestimul
activ
chang
immun
respons
hbvtransgen
mice
respons
also
report
dong
et
al
yang
et
al
anim
studi
cellbas
experi
show
promis
effect
hcv
infect
sever
clinic
studi
conduct
li
et
al
mao
et
al
review
paper
evalu
efficaci
sever
natur
product
report
treatment
chronic
hcv
subject
paper
conclud
result
promis
indic
need
evalu
hcv
case
azzam
et
al
maoto
daiseiryuto
use
common
cold
japan
clinic
studi
conduct
assess
whether
maoto
daiseiryuto
reduc
advers
effect
treatment
chronic
hcv
patient
studi
patient
treat
combin
either
maoto
daiseiryuto
combin
kampo
compar
treatment
alon
kainuma
et
al
b
advers
effect
evalu
base
sever
symptom
selfclassifi
four
categori
use
questionnair
consist
item
score
symptom
discomfort
significantli
lower
combin
therapi
kampo
compar
alon
none
patient
need
interrupt
therapi
side
effect
biochem
paramet
serum
alanin
aminotransferas
serum
hyaluron
acid
level
better
compar
alon
author
propos
administr
kampo
medicin
togeth
treatment
could
increas
sustain
biochem
respons
rate
reduc
liver
fibrosi
two
studi
effect
herbal
mixtur
hcv
infect
mixtur
four
herbal
extract
ifninduc
effect
although
inform
ingredi
clearli
indic
group
conduct
uncontrol
clinic
studi
patient
chronic
hcv
kaji
et
al
studi
claim
month
daili
administr
hcv
rna
level
patient
decreas
improv
malais
bloat
sensat
abdomen
nausea
vomit
observ
signific
number
patient
without
show
seriou
advers
effect
author
conclud
may
safe
use
treatment
chronic
hcv
although
investig
need
perform
obtain
definit
conclus
anoth
studi
report
antihcv
activ
extract
citru
unshiu
peel
aurantii
nobili
pericarpium
inhibit
viral
absorpt
human
acut
lymphoblast
leukemia
cell
line
suzuki
et
al
shosaikoto
wide
use
patient
chronic
hepat
cirrhosi
japan
shimizu
studi
examin
inhibitori
effect
shosaikoto
human
immunodefici
viru
type
replic
peripher
blood
mononuclear
cell
pira
et
al
studi
antihiv
activ
shosaikoto
test
combin
known
antihiv
drug
zidovudin
azt
lamivudin
combin
vitro
experi
indic
shosaikoto
enhanc
antihiv
activ
among
test
combin
author
suggest
combin
therapi
shosaikoto
potenti
chemotherapeut
modal
infect
report
shosaikoto
inhibit
revers
transcriptas
murin
leukemia
viru
hiv
vitro
ono
et
al
activ
may
underli
mechan
antihiv
activ
anoth
vitro
studi
report
polyporu
sclerotium
gardenia
fruit
atractylod
lancea
rhizoma
cnidium
rhizoma
japanes
angelica
root
antihiv
activ
kato
et
al
howev
clinic
trial
shosaikoto
kampo
medicin
hiv
infect
report
far
shosaikoto
initi
test
antihbv
infect
vitro
clinic
studi
vitro
studi
test
peripher
blood
mononuclear
cell
pbmc
patient
chronic
activ
hepat
indic
shosaikoto
increas
antihbv
antibodi
produc
pbmc
dosedepend
manner
kakumu
et
al
clinic
studi
investig
efficaci
shosaikoto
children
chronic
hbv
infect
sustain
liver
diseas
tajiri
et
al
seven
patient
becam
neg
hepat
b
antigen
within
year
studi
hepat
b
antigen
clearanc
rate
shosaikototr
group
higher
control
annual
hepat
b
antigen
clearanc
rate
untreat
patient
group
also
confirm
similar
effect
shosaikoto
hbv
infect
akbar
et
al
chen
et
al
dong
et
al
addit
studi
demonstr
shosaikoto
directli
inhibit
viral
growth
cell
model
chang
et
al
therefor
group
propos
shosaikoto
supplementari
nucleotid
analog
minim
recurr
viremia
discontinu
effect
kakkonto
cutan
herp
simplex
type
infect
mice
describ
nagasaka
et
al
kakkonto
dose
correspond
human
reduc
mortal
mice
reduc
local
skin
lesion
kakkonto
inhibit
viral
growth
vitro
affect
cytokin
product
nk
cell
activ
natur
cytotox
killer
cell
activ
popul
tcell
subset
spleen
cell
infect
mice
delayedtyp
hypersensit
dth
respons
antigen
stronger
kakkontotr
mice
untreat
mice
author
attribut
reduct
mortal
kakkontotr
mice
induct
strong
dth
anoth
studi
investig
protect
effect
hochuekkito
mitomycin
cimmunosuppress
mice
lethal
infect
caus
mitomycin
c
treatment
mice
prevent
oral
hochuekkito
administr
author
conclud
hochuekkito
may
benefici
treatment
infecti
diseas
immunocompromis
patient
receiv
chemotherapeut
drug
kido
et
al
clinic
trial
hochuekkito
infect
report
two
vitro
studi
inhibitori
effect
herbal
extract
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
report
extract
veget
tender
leaf
toona
sinensi
roem
inhibit
growth
sarscov
vitro
chen
et
al
anoth
studi
also
demonstr
six
herbal
extract
gentiana
radix
long
dan
dri
rhizom
gentiana
scabra
dioscorea
rhizoma
yao
tuber
dioscorea
batata
cassia
semen
jue
ming
zi
dri
seed
cassia
tora
loranthi
ramu
sang
ji
sheng
dri
stem
leaf
taxillu
chinensi
two
cibotii
rhizoma
gou
ji
dri
rhizom
cibotium
barometz
inhibit
replic
sarscov
concentr
vero
cell
wen
et
al
interestingli
extract
dioscorea
rhizom
rhizom
cibotii
found
inhibit
sarscov
proteas
activ
among
extract
test
bk
virusassoci
hemorrhag
cystiti
bkvhc
common
problem
aris
occasion
hematopoiet
stem
cell
transplant
group
examin
efficaci
choreito
treat
bkvhc
children
underw
allogen
hematopoiet
stem
cell
transplant
kawashima
et
al
durat
complet
resolut
hematuria
significantli
shorter
choreitotr
group
median
day
rang
day
compar
nonchoreito
group
median
day
rang
day
p
bkv
load
urin
decreas
month
choreito
treatment
advers
effect
observ
therefor
author
suggest
choreito
may
safe
promis
therapi
hemostasi
bkvhc
hematopoiet
stem
cell
transplant
human
papillomaviru
hpv
oncoprotein
ubiquit
express
precursor
lesion
cervic
cancer
target
hpv
therapeut
vaccin
studi
demonstr
juzentaihoto
hochuekkito
adjuv
activ
oral
vaccin
recombin
lactobacillu
casei
express
mice
taguchi
et
al
oral
immun
mice
mucos
adjuv
heatlabil
enterotoxin
subunit
ltb
promot
system
type
tcell
respons
similar
effect
observ
juzentaihoto
hochuekkito
adjuv
oral
administr
plu
either
japanes
kampo
medicin
ltb
enhanc
mucos
type
tcell
respons
approxim
threefold
administr
alon
secret
intestin
lumen
enhanc
juzentaihoto
hochuekkito
ltb
oral
administr
final
kampo
medicin
enhanc
mucos
type
immun
respons
oral
immun
antigen
synergist
lactobacillu
ltb
therefor
author
suggest
juzentaihoto
hochuekkito
may
excel
adjuv
oral
lactobacillusbas
vaccin
may
potenti
elicit
extrem
high
mucos
cytotox
immun
respons
hpvassoci
neoplast
lesion
c
albican
caus
major
opportunist
fungal
infect
observ
patient
treatment
immunesuppress
drug
other
hiv
patient
group
suggest
sever
kampo
medicin
might
effect
therapeut
agent
candidiasi
immunosuppress
patient
protect
effect
juzentaihoto
ingredi
candida
infect
investig
use
immunosuppress
mice
abe
et
al
icr
mice
inject
prednisolon
cyclophosphamid
oral
administ
gkg
juzentaihoto
daili
intraven
infect
lethal
dose
c
albican
juzentaihoto
treatment
prolong
life
span
infect
mice
compar
control
mice
similar
protect
effect
obtain
treatment
ingredi
ginseng
radix
glycyrrhiza
radix
lancea
rhizoma
cnidium
rhizoma
ninjinyoeito
also
similar
effect
mice
immunosuppress
cyclophosphamid
abe
et
al
foodborn
pathogen
l
monocytogen
caus
ill
mainli
pregnant
women
newborn
elderli
immunocompromis
peopl
two
kampo
medicin
indic
effect
l
monocytogen
infect
mice
shosaikoto
first
describ
prevent
lethal
effect
l
monocytogen
intraperiton
ip
inject
growth
l
monocytogen
periton
caviti
liver
suppress
day
infect
bactericid
activ
periton
macrophag
shosaikototr
mice
maintain
day
ip
inject
kill
l
monocytogen
wherea
activ
control
mous
macrophag
decreas
author
suggest
augment
accumul
macrophag
mainten
bactericid
activ
may
main
mechan
resist
shosaikototr
mice
effect
hochuekkito
l
monocytogen
infect
report
mous
model
mice
oral
administ
hochuekkito
day
gkg
per
day
intraven
iv
ip
infect
l
monocytogen
surviv
rate
mice
infect
iv
day
infect
ip
day
last
administr
increas
number
bacteria
spleen
liver
increas
kill
ivinfect
mice
day
nonadminist
group
wherea
number
bacteria
hochuekkitopretr
mice
increas
rel
slowli
day
decreas
day
day
similar
effect
observ
ipinfect
mice
periton
macrophag
hochuekkitotr
mice
show
enhanc
activ
kill
l
monocytogen
vitro
within
min
ingest
bacteria
similar
effect
observ
mice
undergo
restraint
stress
treatment
infant
mice
yamaoka
et
al
yamaoka
et
al
infant
mice
cell
increas
hochuekkito
treatment
independ
defici
antigenpres
function
p
acn
gramposit
commens
bacterium
caus
acn
skin
p
acn
releas
lipas
produc
fatti
acid
digest
sebum
creat
inflamm
skin
sever
kampo
medicin
ingredi
describ
inhibitori
effect
growth
bacteria
report
describ
orengedokuto
ingredi
coptidi
rhizoma
phellodendri
cortex
higaki
et
al
higaki
et
al
higaki
et
al
jumihaidokuto
higaki
et
al
higaki
et
al
unseiin
higaki
morohashi
keigairengyoto
higaki
et
al
higaki
et
al
inhibit
growth
p
acn
lipas
activ
therefor
kampo
medicin
use
acn
h
pylori
gramneg
bacterium
infect
stomach
whose
infect
major
caus
gastroduoden
diseas
human
erad
h
pylori
antibiot
effect
treatment
howev
variabl
preval
resist
organ
develop
fakheri
et
al
studi
investig
antibacteri
effect
hochuekkito
h
pylori
infect
vivo
vitro
yan
et
al
vitro
experi
demonstr
hochuekkito
inhibit
growth
antibioticresist
strain
h
pylori
well
antibioticsensit
strain
dose
mgml
vivo
experi
mice
oral
administ
hochuekkito
day
inocul
h
pylori
show
bacteri
load
stomach
significantli
reduc
hochuekkito
group
compar
control
group
hochuekkito
administr
induc
gastric
mucosa
signific
differ
bacteri
load
control
hochuekkitotr
group
genedefici
mice
therefor
author
suggest
antibacteri
effect
hochuekkito
partli
due
induct
possibl
clinic
use
treatment
h
pylori
infect
infect
bacterium
v
cholera
small
intestin
caus
sever
diarrheal
diseas
cholera
caus
agent
cholera
cholera
toxin
ct
virul
factor
secret
v
cholera
studi
indic
daiokanzoto
inhibit
ct
activ
adpribosyl
chines
hamster
ovari
cell
elong
identifi
activ
compound
kampo
medicin
oi
et
al
among
sever
compon
purifi
daio
extract
rhubarb
galloyltannin
compound
character
polygal
structur
effect
one
synthes
gallat
analog
similar
rhubarb
galloyltannin
inhibit
ct
activ
includ
adpribosyl
elong
chines
hamster
ovari
cell
fluid
accumul
ileal
loop
therefor
author
claim
kampo
formul
gallat
compon
might
effect
adjunct
therapi
oral
rehydr
solut
sever
diarrhea
cholera
p
gingivali
gramneg
bacterium
implic
certain
form
periodont
diseas
sever
kampo
medicin
report
inhibit
p
gingivali
growth
suggest
effect
control
periodont
diseas
group
test
sever
kampo
medicin
p
gingivali
growth
adher
epitheli
cell
proteinas
activ
liao
et
al
among
kampo
medicin
test
sanoshashinto
strongest
inhibitori
effect
test
identifi
respons
compound
present
chines
rhubarb
one
major
compon
sanoshashinto
anthraquinon
alo
emodin
rhein
anthraquinon
also
inhibit
adher
p
gingivali
oral
epitheli
cell
reduc
proteinas
activ
strongest
antiadher
activ
observ
kampo
medicin
mashiningan
extract
granul
contain
rhubarb
therefor
author
claim
kampo
medicin
contain
rhubarb
anthraquinon
deriv
may
effect
control
periodont
diseas
capac
inhibit
p
gingivali
growth
virul
properti
certain
oral
microorgan
implic
intensifi
inflammatori
process
aggrav
ulcer
format
oral
mucos
om
cancer
patient
chemotherapi
radiotherapi
kampo
medicin
hangeshashinto
hst
investig
antimicrobi
activ
sever
bacteria
fungi
fukamachi
et
al
hst
extract
inhibit
growth
gramneg
bacteria
includ
fusobacterium
nucleatum
p
gingivali
porphyromona
endodontali
prevotella
intermedia
prevotella
melaninogenica
tannerella
forsythia
treponema
denticola
porphyromona
asaccharolytica
less
inhibitori
effect
gramposit
bacteria
fungal
strain
observ
activ
ingredi
hst
identifi
baicalein
berberin
coptisin
homogentis
acid
author
suggest
hst
may
use
treatment
om
patient
undergo
anticanc
treatment
pyogen
infect
caus
necrot
fasciiti
streptococc
toxic
shock
syndrom
efficaci
kampo
medicin
hainosankyuto
treatment
pyogen
skin
infect
investig
vivo
experi
use
mice
minami
et
al
oral
administr
hainosankyuto
infect
mice
consecut
day
increas
surviv
rate
reduc
size
local
skin
lesion
compar
control
mice
hainosankyuto
attenu
bacteri
load
blood
increas
macrophag
phagocyt
activ
mice
increas
level
decreas
level
serum
pyogenesinfect
mice
author
conclud
hainosankyuto
may
use
treatment
pyogen
infect
prophylact
therapeut
